Loading...

Home
Stock
JNJ

JNJ Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

243.220

Open

240.870

VWAP

241.90

Vol

4.07M

Mkt Cap

579.34B

Low

240.040

Amount

984.50M

EV/EBITDA(TTM)

17.65

Total Shares

2.41B

EV

607.17B

EV/OCF(TTM)

24.75

P/S(TTM)

6.20

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

Show More

Events Timeline

(ET)

2026-03-08

22:30:00

KKR Plans to Sell CoolIT Systems for Over $3B

2026-03-08

17:00:00

Dr. Vinay Prasad to Leave Agency at End of April

2026-03-05 (ET)

2026-03-05

16:00:00

Johnson & Johnson's Tecvayli and Darzalex Approved by FDA for Multiple Myeloma

2026-03-05

13:40:00

Johnson & Johnson's Janssen Biotech Receives FDA Approval for New Multiple Myeloma Treatment

2026-03-03 (ET)

2026-03-03

08:10:00

Johnson & Johnson's nipocalimaba Receives FDA Fast Track Designation

2026-02-26 (ET)

2026-02-26

15:00:00

Johnson & Johnson Reports Preliminary Results of Pasritamig with Docetaxel for Prostate Cancer

2026-02-24 (ET)

2026-02-24

16:30:00

Johnson & Johnson Submits Imaavy Application to FDA for Autoimmune Hemolytic Anemia

2026-02-23 (ET)

2026-02-23

11:30:00

Johnson & Johnson Receives EU Approval for Rybrevant Extension

News

NASDAQ.COM

13:04 PMNASDAQ.COM

PinnedJohnson & Johnson's AKEEGA Approved by European Commission

Drug Approval: Johnson & Johnson announced that its dual-action drug AKEEGA has been approved by the European Commission for treating adult patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, marking a significant advancement in cancer treatment.
Clinical Trial Support: The approval is supported by data from the Phase 3 AMPLITUDE trial, which demonstrated significant benefits in BRCA-mutated patients, further solidifying its application potential in high-risk patient groups.
Market Outlook: According to GlobalData's Pharma Intelligence Centre, AKEEGA is projected to generate $178 million in revenue by 2031, indicating strong growth potential for Johnson & Johnson in the prostate cancer treatment market.
Stock Performance: Johnson & Johnson's stock has traded between $141.50 and $251.71 over the past year, with the latest closing price at $240.40, reflecting positive market sentiment following the drug approval.

NASDAQ.COM

03-08NASDAQ.COM

Strong Dividends and Innovation Drive Healthcare Stocks

Strong Dividend Record: Johnson & Johnson has raised its dividend for 50 consecutive years and expects to surpass $100 billion in sales this year for the first time, showcasing its stability and appeal to income-seeking investors amid economic fluctuations.
Innovative Product Pipeline: Johnson & Johnson is awaiting approval for its robotic-assisted surgery system, Ottava, which could serve as a significant growth driver, while the company is also conducting dozens of clinical trials to expand its pharmaceutical portfolio.
Leader in Animal Health: Zoetis has increased its dividend by 458% over the past decade, and despite facing safety concerns and competitive pressures, the launch of new products like Lenivia and Portela will support its continued growth in the pet healthcare market.
Pet Ownership Trend Among Youth: Zoetis is capitalizing on the trend of younger generations increasingly choosing to own pets over having children by introducing innovative medications like Apoquel, which is expected to further solidify its market position and drive future revenue growth.

Fool

The Investment Advantage of High-Quality Dividend Stocks

Dividend Return Comparison: A study by Hartford Funds and Ned Davis Research reveals that dividend stocks have achieved an annualized return of 9.2% from 1973 to 2024, significantly outperforming non-dividend payers at 4.31%, highlighting the long-term investment value of dividend stocks.
Microsoft's Dividend Power: Microsoft is set to pay over $27 billion in dividends over the next year, with a modest yield of 0.9%, yet its rapid growth in cloud computing and AI solutions provides robust cash flow support, ensuring substantial returns for shareholders.
ExxonMobil's Stability: ExxonMobil's annual dividend payout of $17.18 billion benefits from its integrated operating model, which helps maintain steady cash flow amid oil price fluctuations, especially with current geopolitical tensions driving prices higher, enhancing its outlook.
Apple's Dividends and Buybacks: Apple pays $15.27 billion in annual dividends and has repurchased $841 billion in stock since fiscal 2013, demonstrating strong cash flow and commitment to shareholder returns, while its pivot to subscription services is expected to further enhance future profitability.

Fool

Top Dividend Stocks to Buy: Johnson & Johnson and Zoetis

Johnson & Johnson's Stability: Johnson & Johnson expects its 2023 sales to exceed $100 billion for the first time, demonstrating strong revenue and earnings growth despite challenges like patent expirations and drug price negotiations, highlighting its resilience and long-term investment value in the healthcare sector.
Innovation-Driven Growth: The company is awaiting approval for its robotic-assisted surgery system, Ottava, which could be a significant growth driver, while its pharmaceutical pipeline includes dozens of ongoing clinical trials that enhance its competitive position in the market.
Zoetis' Market Leadership: As a leader in animal health, Zoetis faces challenges from safety concerns, but the approval of new products Lenivia and Portela presents new growth opportunities, especially given their more favorable dosing frequency compared to predecessors.
Dividend Growth Potential: Zoetis has increased its dividend by an impressive 458% over the past decade, reflecting its strong cash flow and profitability, making it an attractive option for income-seeking investors, particularly as younger generations increasingly choose pet ownership over having children.

NASDAQ.COM

03-08NASDAQ.COM

Dividend Stocks Outperform Non-Payers Significantly

Dividend Return Advantage: A study by Hartford Funds and Ned Davis Research reveals that dividend stocks have achieved an annualized return of 9.2% from 1973 to 2024, more than double the 4.31% of non-payers, highlighting their stability and attractiveness for long-term investors.
Microsoft's Dividend Power: Microsoft pays a quarterly dividend of $0.91, projecting over $27 billion in payouts to shareholders in the coming year; despite a low yield of 0.9%, its rapid growth in cloud computing and AI solutions provides robust cash flow support.
ExxonMobil's Robust Model: ExxonMobil's quarterly dividend of $1.03 translates to nearly $17.2 billion annually, with its integrated operating model across upstream, midstream, and downstream assets enhancing its ability to withstand crude oil price fluctuations.
Strong Bank Stock Returns: JPMorgan Chase's quarterly dividend of $1.50 results in annual payouts of $16.2 billion, benefiting from the Federal Reserve's rate hikes, as banks typically outperform during economic expansions, ensuring steady capital returns.

seekingalpha

03-07seekingalpha

FDA Vaccines Head Vinay Prasad to Depart Again

Leadership Change: Vinay Prasad, head of the FDA's vaccines unit, is set to leave at the end of next month, marking the second high-level departure within a year, which may impact the continuity and stability of vaccine policies.
Background: Prasad joined the FDA in May 2025, succeeding the abruptly resigned Peter Marks, and was appointed as the chief medical and scientific officer in June, highlighting his significance in the vaccine sector.
Controversial Decisions: During his tenure, Prasad oversaw several controversial decisions, including the FDA's response to Elevidys, a treatment linked to deaths, leading to his sudden departure in late July, reflecting the challenges the FDA faces in handling complex medical issues.
Achievements and Return: Despite challenges, Prasad achieved a record number of approvals in December, demonstrating his accomplishments during his brief tenure, and will return to the University of California, San Francisco, to continue his academic career.

Wall Street analysts forecast JNJ stock price to rise

20 Analyst Rating

Wall Street analysts forecast JNJ stock price to rise

13 Buy

7 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

190.00

Averages

218.50

High

240.00

Current: 0.000

Low

190.00

Averages

218.50

High

240.00

JPMorgan

Neutral

maintain

$225 -> $250

AI Analysis

2026-03-05

New

Reason

JPMorgan

Price Target

$225 -> $250

AI Analysis

2026-03-05

New

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Johnson & Johnson to $250 from $225 and keeps a Neutral rating on the shares. The firm cites its increased Tremfya estimates for the target boost. The recent ramp of Tremfya in inflammatory bowel disease has driven outperformance for the product, the analyst tells investors in a research note.

BofA

Jason Gerberry

Neutral

maintain

$227 -> $253

2026-03-03

Reason

BofA

Jason Gerberry

Price Target

$227 -> $253

2026-03-03

maintain

Neutral

Reason

BofA analyst Jason Gerberry raised the firm's price target on Johnson & Johnson to $253 from $227 and keeps a Neutral rating on the shares. The firm increased its J&J out-year revenue estimates to reflect updated views on certain near-to-market pipeline assets, notably Tecvayli and Inlexzo, along with what it sees as a knock-on effect from strong Tecvayli data to Darzalex treatment duration.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JNJ

Unlock Now

Valuation Metrics

The current forward P/E ratio for Johnson & Johnson (JNJ.N) is 18.82, compared to its 5-year average forward P/E of 16.16. For a more detailed relative valuation and DCF analysis to assess Johnson & Johnson's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

16.16

Current PE

18.82

Overvalued PE

17.41

Undervalued PE

14.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

12.99

Current EV/EBITDA

15.18

Overvalued EV/EBITDA

13.87

Undervalued EV/EBITDA

12.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

4.50

Current PS

5.16

Overvalued PS

4.85

Undervalued PS

4.15

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

whats a big gane stock

Intellectia · 5293 candidates

Ticker

Name

Market Cap$

NVIDIA Corp

4.45T

Apple Inc

3.85T

Alphabet Inc

3.67T

Microsoft Corp

3.01T

Amazon.com Inc

2.33T

Taiwan Semiconductor Manufacturing Co Ltd

1.85T

principales acciones que paguen dividendos

Intellectia · 96 candidates

Dividend Yield Ttm: 2 - 8Dividend Payout Ratio: 20.00 - 80.00Is Index Component: GSPCDividend 5yr Cagr: >= 0

Ticker

Name

Market Cap$

Exxon Mobil Corp

642.60B

Johnson & Johnson

599.00B

Home Depot Inc

369.15B

Coca-Cola Co

345.00B

Cisco Systems Inc

313.70B

Merck & Co Inc

300.17B

Intellectia · 59 candidates

Market Cap: >= 80.00BDividend Yield Ttm: 1 - 6Net Margin: >= 5.00Return On Equity: >= 10.0%Is Index Component: GSPC, DJI

Ticker

Name

Market Cap$

JPMorgan Chase & Co

809.92B

Exxon Mobil Corp

635.43B

Johnson & Johnson

598.69B

AbbVie Inc

410.36B

Procter & Gamble Co

390.70B

Home Depot Inc

379.01B

Featured Screeners

Intellectia · 45 candidates

Market Cap: >= 20.00BEps 5yr Cagr: >= 15Pe Ttm: 15 - 30Moving Average Relationship: PriceAboveMA200Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Taiwan Semiconductor Manufacturing Co Ltd

1.94T

JPMorgan Chase & Co

809.92B

Johnson & Johnson

598.69B

Micron Technology Inc

464.13B

Novartis

321.75B

HSBC Holdings PLC

320.01B

stock to buy today

Intellectia · 20 candidates

Market Cap: >= 50.00BNet Margin: >= 15.00Pe Ttm: 10 - 25Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

Anglogold Ashanti PLC

63.67B

Agnico Eagle Mines Ltd

123.28B

Canadian National Railway Co

67.41B

Newmont Corporation

138.67B

Novartis

315.82B

CSX Corp

79.31B

which are the s&p 500 companies

Intellectia · 476 candidates

Is Index Component: GSPC

Ticker

Name

Market Cap$

NVIDIA Corp

4.61T

Apple Inc

3.88T

Alphabet Inc

3.81T

Microsoft Corp

2.95T

Amazon.com Inc

2.26T

Meta Platforms Inc

1.66T

Intellectia · 86 candidates

Net Margin: >= 10.00Pe Ttm: 10 - 30Return On Equity: >= 10.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Berkshire Hathaway Inc

1.08T

JPMorgan Chase & Co

832.79B

Johnson & Johnson

590.40B

Micron Technology Inc

473.78B

Bank of America Corp

384.86B

Procter & Gamble Co

366.54B

medical and tech

Intellectia · 1801 candidates

Sector: Financial Technology (Fintech) & Infrastructure, Healthcare, Healthcare Services & Equipment, Technology, Technology EquipmentList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

NVIDIA Corp

4.57T

Apple Inc

3.88T

Alphabet Inc

3.68T

Microsoft Corp

2.97T

Taiwan Semiconductor Manufacturing Co Ltd

1.88T

Meta Platforms Inc

1.63T

what stock should I buy

Intellectia · 96 candidates

Market Cap: >= 10.00BQuarter Revenue Yoy Growth: >= 5.0%Pe Ttm: 10 - 30Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX

Ticker

Name

Market Cap$

Western Digital Corp

96.32B

Micron Technology Inc

449.96B

Newmont Corporation

133.47B

Huntington Ingalls Industries Inc

16.40B

Bunge Global ltd

23.57B

Monolithic Power Systems Inc

57.14B

give me top 5 screener

Intellectia · 62 candidates

Region: USMarket Cap Category: large, megaNet Margin: >= 10.00Eps 5yr Cagr: >= 10Pe Ttm: 10 - 35Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Alphabet Inc

3.70T

JPMorgan Chase & Co

823.62B

Johnson & Johnson

586.69B

Micron Technology Inc

463.33B

Bank of America Corp

379.02B

Caterpillar Inc

362.31B

Whales Holding JNJ

Caisse des Dépôts et Consignations

Chickasaw Capital Management, LLC

Pacific Investment Management Company LLC

GQG Partners, LLC

SAMA Foreign Holdings

Old Mutual Investment Group South Africa (Pty) Limited

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is Johnson & Johnson (JNJ) stock price today?

The current price of JNJ is 242.43 USD — it has increased 0.84

What is Johnson & Johnson (JNJ)'s business?

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

What is the price predicton of JNJ Stock?

Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Johnson & Johnson (JNJ)'s revenue for the last quarter?

Johnson & Johnson revenue for the last quarter amounts to 24.56B USD, increased 9.08

What is Johnson & Johnson (JNJ)'s earnings per share (EPS) for the last quarter?

Johnson & Johnson. EPS for the last quarter amounts to 2.09 USD, increased 48.23

How many employees does Johnson & Johnson (JNJ). have?

Johnson & Johnson (JNJ) has 138200 emplpoyees as of March 09 2026.

What is Johnson & Johnson (JNJ) market cap?

Today JNJ has the market capitalization of 579.34B USD.